Payment overview · 2025
General Payments
$368.91
15 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher Sprando
Allopathic & Osteopathic Physicians|Family Medicine · GROVE CITY, PA · NPI 1700892684
Verified facts
What the public records show
CMS Open Payments records show Christopher Sprando received $368.91 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 85.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 395 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $315.25 | 85.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.51 | 6.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.90 | 4.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.25 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $304.37 | 13 |
| Education | $64.54 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $309.77 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.30 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $5.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 252 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 395 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
252 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
252 | 53 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
96 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
395 | 65 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1186 | 324 |
| Lisinopril | Lisinopril | 1031 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 672 | 166 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 141 |
| Gabapentin | Gabapentin | 569 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 539 | 127 |
| Furosemide | Furosemide | 523 | 106 |
| Omeprazole | Omeprazole | 516 | 131 |
| Losartan Potassium | Losartan Potassium | 495 | 126 |
| Potassium Chloride | Potassium Chloride | 486 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 467 | 110 |
| Metoprolol Tartrate | Metoprolol Tartrate | 398 | 87 |
| Ozempic | Semaglutide | 395 | 65 |
| Eliquis | Apixaban | 389 | 57 |
| Metformin Hcl | Metformin Hcl | 372 | 117 |
| Alendronate Sodium | Alendronate Sodium | 350 | 82 |
| Simvastatin | Simvastatin | 315 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 285 | 86 |
| Jardiance | Empagliflozin | 252 | 53 |
| Sertraline Hcl | Sertraline Hcl | 248 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 216 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 211 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 46 |
| Xarelto | Rivaroxaban | 182 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 48 |
| Famotidine | Famotidine | 156 | 38 |
| Atenolol | Atenolol | 139 | 37 |
| Meloxicam | Meloxicam | 139 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 42 |
| Trazodone Hcl | Trazodone Hcl | 128 | 28 |
| Allopurinol | Allopurinol | 125 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 122 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 118 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 104 | 13 |
| Montelukast Sodium | Montelukast Sodium | 102 | 27 |
| Bupropion Xl | Bupropion Hcl | 101 | 25 |
| Carvedilol | Carvedilol | 101 | 25 |
| Tramadol Hcl | Tramadol Hcl | 101 | 27 |
| Prednisone | Prednisone | 100 | 66 |
| Spironolactone | Spironolactone | 98 | 25 |
| Trulicity | Dulaglutide | 96 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 31 |
| Propranolol Hcl | Propranolol Hcl | 93 | 15 |
| Mirtazapine | Mirtazapine | 90 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 90 | 24 |
| Buspirone Hcl | Buspirone Hcl | 89 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 87 | 50 |
| Baclofen | Baclofen | 85 | 13 |
| Donepezil Hcl | Donepezil Hcl | 83 | 13 |
| Glimepiride | Glimepiride | 83 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 79 | 16 |
| Lorazepam | Lorazepam | 77 | 37 |
| Memantine Hcl | Memantine Hcl | 76 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 76 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 22 |
| Celecoxib | Celecoxib | 73 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 17 |
| Synthroid | Levothyroxine Sodium | 71 | 23 |
| Warfarin Sodium | Warfarin Sodium | 70 | 15 |
| Finasteride | Finasteride | 68 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 54 |
| Clonidine Hcl | Clonidine Hcl | 64 | 18 |
| Ezetimibe | Ezetimibe | 60 | 16 |
| Irbesartan | Irbesartan | 60 | 12 |
| Lamotrigine | Lamotrigine | 59 | suppressed |
| Latanoprost | Latanoprost | 55 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 16 |
| Meclizine Hcl | Meclizine Hcl | 51 | 25 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 28 |
| Glipizide Er | Glipizide | 50 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 11 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Valsartan | Valsartan | 48 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 12 |
| Benazepril Hcl | Benazepril Hcl | 44 | 12 |
| Glipizide | Glipizide | 44 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 17 |
| Sucralfate | Sucralfate | 43 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | suppressed |
| Ibuprofen | Ibuprofen | 40 | 18 |
| Topiramate | Topiramate | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 13 |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 31 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Naproxen | Naproxen | 29 | 11 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Indapamide | Indapamide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 14 |
| Alprazolam | Alprazolam | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Risperidone | Risperidone | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Nystatin | Nystatin | 19 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 15 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Zylet | Tobramycin/Lotepred Etab | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Asmanex | Mometasone Furoate | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $368.91 · 15 records | Novo Nordisk Inc | JARDIANCE, Kerendia, MOUNJARO, Ozempic, Rybelsus, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error